TY - JOUR A1 - Lüthy, Anja T1 - Employer Branding: Was Kliniken von anderen Branchen lernen können JF - In: HeilberufeScience 3 (2012), S. 18 Y1 - 2012 UR - link.springer.com/content/pdf/10.1007%2Fs16024-012-0128-x SP - 18 ER - TY - CHAP A1 - Buchmann, Uta A1 - Lüthy, Anja T1 - Umfassendes Dienstleistungsmarketing – Pflichtaufgabe für Krankenhäuser T2 - In: Patient Krankenhaus : Wie Kliniken der Spagat zwischen Ökonomie und medizinischer Spitzenleistung gelingt / hrsg. von Ulrich Korff. - Wiesbaden : Gabler, 2012. - ISBN: 978-3-8349-7189-0; 978-3-8349-3433-8 (ISBN der Printausgabe) N2 - Krankenhäuser müssen noch viel lernen, wenn es darum geht, ihre Leistungen kundenorientiert – auch über die medizinischen Kernleistungen hinaus – erfolgreich zu vermarkten. Von einem systematischen Dienstleistungsmarketing sind viele Häuser noch weit entfernt. Ein professionell praktiziertes Dienstleistungsmarketing – von der grundlegenden Strategie bis zur operativen Umsetzung – ist jedoch die Grundvoraussetzung, um sich im Wettbewerb um Patienten erfolgreich zu behaupten. Y1 - 2012 UR - http://link.springer.com/chapter/10.1007/978-3-8349-7189-0_16 SP - 177 EP - 191 ER - TY - JOUR A1 - Gebauer, Gerhard A1 - Mueller, Natalia A1 - Fehm, Tanja A1 - Berkholz, Alexander A1 - Beck, Eberhard A1 - Jaeger, Wolfram A1 - Licht, Peter T1 - Expression and regulation of luteinizing hormone/human chorionic gonadotropin receptors in ovarian cancer and its correlation to human chorionic gonadotropin–doxorubicin sensitivity JF - In: American Journal of Obstetrics & Gynecology 190 (2004), Iss. 6, pp. 1621-1628 N2 - Objective Ovarian cancer cell lines and tissues express gonadotropin receptors. Conjugation of cytostatics to ligands of these receptors may increase the specificity of cytotoxic drugs. Study design Toxicity of doxorubicin–human chorionic gonadotropin conjugates was determined in 4 ovarian cancer cell lines. Expression and regulation of luteinizing hormone/human chorionic gonadotropin receptors were analyzed before and after treatment with human chorionic gonadotropin, epidermal growth factor, and 8-bromo-cyclic adenosine monophosphate with a nested reverse transcriptase–polymerase chain reaction approach. Results Toxicity of human chorionic gonadotropin–doxorubicin conjugates was increased compared with unconjugated doxorubicin in OVCAR-3 cells. However, drug conjugates failed to demonstrate increased toxicity in other cell lines, especially after preincubation with human chorionic gonadotropin. All cell lines expressed luteinizing hormone/human chorionic gonadotropin receptors. Receptor expression in OVCAR-3 cells was not effected by human chorionic gonadotropin, endothelial growth factor, or 8-bromo-cyclic adenosine monophosphate treatment. In other cell lines, receptor expression was down-regulated by these agents. Conclusion Cytotoxic activity of doxorubicin was increased specifically by conjugation to human chorionic gonadotropin. However, the regulation of luteinizing hormone/human chorionic gonadotropin receptor expression and other compounds may reduce the drug-uptake of the conjugates. Y1 - 2004 SP - 1621 EP - 1624 ER - TY - JOUR A1 - Gebauer, Gerhard A1 - Fehm, Tanja A1 - Beck, Eberhard A1 - Berkholz, Alexander A1 - Licht, Peter A1 - Jäger, Wolfram T1 - Cytotoxic effect of conjugates of doxorubicin and human chorionic gonadotropin (hCG) in breast cancer cells JF - In: Breast Cancer Research and Treatment 77(2003)2, pp. 125-131 N2 - Cytotoxic activity of drug conjugates of human chorionic gonadotropin (hCG) and doxorubicin alone was investigated compared to doxorubicin in breast cancer cells with and without expression of hCG receptors. Expression of hCG receptor was determined in MCF-7 and MB231 breast cancer cell line using a multiplex nested rt-PCR approach. The entire sequence of mRNA encoding for hCG receptor was detected in MCF-7 but not in MB231 breast cancer cell line. Cytostatic effect of doxorubicin–hCG conjugates was investigated in these cell lines in comparison to unconjugated doxorubicin. The number of viable cells was determined after 24, 48, 72, 96, and 120 h. To exclude non-specific uptake of the carrier hCG from the culture media, a similar experiment was performed with albumin–doxorubicin conjugates. The number of viable cells decreased in a concentration depending manner after doxorubicin and hCG–doxorubicin conjugate treatment. However, the cytotoxic effect of hCG–doxorubicin conjugate was 10-fold increased compared to unconjugated doxorubin in hCG-receptor positive MCF-7 but not in hCG-receptor negative MB231 cells. Albumin–doxorubicin conjugates showed no increased toxicity compared to doxorubicin. We conclude that the cytotoxic effect of hCG–doxorubicin conjugates is mediated specifically via the hCG receptor. By using hCG conjugates, the development of more selective cytostatics can be achieved. Y1 - 2003 UR - http://link.springer.com/article/10.1023%2FA%3A1021301001208 SP - 125 EP - 131 ER - TY - JOUR A1 - Gebauer, Gerhard A1 - Fehm, Tanja A1 - Merkle, Elisabeth A1 - Beck, Eberhard A1 - Lang, Norbert A1 - Jäger, Wolfram T1 - Epithelial Cells in Bone Marrow of Breast Cancer Patients at Time of Primary Surgery: Clinical Outcome During Long-Term Follow-Up JF - In: J. Clin. Oncol. 19(2001)16, 3669 – 3674 N2 - PURPOSE: To evaluate the detection of epithelial cells in bone marrow of breast cancer patients as an indicator of metastatic disease. PATIENTS AND METHODS: Between 1989 and 1994, bone marrow biopsies were performed on 393 breast cancer patients during primary surgery. Specimens were stained immunocytochemically for epithelial cells expressing cytokeratins or the epithelial membrane antigen. The long-term outcomes of these patients were analyzed in this study. RESULTS: In 166 of 393 patients, epithelial cells were found in bone marrow (BM) aspirates. These patients were designated BM+. The rate of tumor recurrence or cancer-related death was significantly higher in BM+ patients than in BM− patients. Multivariate analysis using the Cox regression model revealed BM status as a prognostic parameter independent of tumor size and axillary lymph node status. However, tumor size and axillary lymph node status were clearly superior prognostic parameters. CONCLUSION: Disseminated epithelial cells in BM are associated with poor clinical outcome in breast cancer patients. However, the presence of these cells is not a sufficient parameter to predict growing metastases in the majority of patients, suggesting that epithelial cells in the BM of breast cancer patients at the time of surgery have limited metastatic potential. The role of these cells needs to be further evaluated. Y1 - 2001 SP - 3669 EP - 3674 ER - TY - JOUR A1 - Merkle, E. A1 - Ackermann, S. A1 - Beck, Eberhard A1 - Jäger, W. A1 - Lang, N. T1 - High-Dose versus Low-Dose Cisplatin Chemotherapy plus Treosulfan in Epithelial Ovarian Carcinoma FIGO II–IV: Results of a Prospective Randomized Trial JF - In: Onkologie 23(2000)3, 232-238 N2 - Summary Background: Combination chemotherapies of platinum compounds with alkylating agents have been the standard treatment for patients with advanced ovarian carcinoma over the last decades. The recent development of taxans has added a group of new promising agents; however, long-term results are not yet available. Platin derivates have proven to be an indispensable part in combination chemotherapies for ovarian carcinoma. The dose intensity of cisplatin is, however, still a matter of debate. We report on the long-term results of a prospective randomized trial comparing two dosages of cisplatin combined with treosulfan in patients with advanced epithelial ovarian cancer. Patients and Methods: Between 1988 and 1995, 125 patients with ovarian cancer (FIGO stage II–IV) were randomized to receive 4 cycles (28-day intervals) of either cisplatin 100 mg/m2 (high dose, HD) or 50 mg/m2 (low dose, LD) in combination with 5 g/m2 treosulfan after primary cytoreductive surgery. Postoperative residual tumor was absent in 39 patients (HD: 16; LD: 23), < 2 cm in 61 patients (HD: 36; LD: 25) and > 2 cm in 25 patients (HD: 13; LD: 12). 65 and 60 patients received HD and LD cisplatin, respectively. Second-look surgery was optional. Results:The overall response rate was 70.0% (HD: 70.9%; LD: 68.9%). Pathological complete response (CR) was seen in 45 patients (37.5%), clinical CR in 23 patients (19.2%), partial response (PR) in 16 patients (13.3%), stable disease (SD) in 2 patients, and progression of disease (PD) in 34 patients (28.3%). 5 patients were not assessable for response. Overall median survival was 25.6 (HD: 26.9, LD: 25.2) months. The overall disease-free survival for responders was 19.6 and 24.7 months (HD and LD, respectively). HD chemotherapy did not result in any significant survival benefit in completely resected patients: HD: 39.8 months versus LD: 49.5 months. In suboptimally debulked patients (residual tumor < 2 cm), median survival was 24.1 months (HD) versus 22.6 months (LD). In patients with residual tumors > 2 cm median survival was 14.6 months (HD) versus 15.5 months (LD). Significantly less side effects were seen in the LD group: anemia (p = 0.008); nephrotoxicity (p = 0.014); alopecia (p = 0.017). Conclusions: Our data suggest that LD cisplatin-based chemotherapy is as effective as HD chemotherapy in patients with advanced epithelial ovarian cancer, but is far less toxic. Copyright © 2000 S. Karger GmbH, Freiburg Y1 - 2000 SP - 232 EP - 238 ER - TY - CHAP A1 - Beck, Eberhard A1 - Sciacca, Laura A1 - Pandini, Giuseppe A1 - Jaeger, Wolfram A1 - Pezzino, Vincenzo T1 - Measurement of IGF-1 Receptor Content in Tissues and Cell Lines by Radioimmunoassay (RIA) and ELISA Techniques T2 - In: Ovarian Cancer : Methods and Protocols / ed. by John M. S. Bartlett. - Totowa, NJ : Humana Press, 2001. - Totowa, NJ : Humana Press, 2001. - (Methods in Molecular Medicine™ ; 39). - ISBN: 978-1-592-59071-1; 978-0-89603-583-6 (ISBN der Printausgabe) N2 - The IGF-1 receptor (IGF-1-R) belongs to the tyrosine kinase growth factor receptor family. It is structurally similar to, but distinct from, the insulin receptor, with which it shares a 70% homology. As expected, it crossreacts with insulin and, vice versa, insulin receptor crossreacts with IGF-1. Numerous studies suggest that IGF-1-R is very important for mitogenesis and is essential for phenotype transformation, at least in rodents (1). In particular, the IGF-1-R has been described in human breast cancer (2-4) and ovarian cancer (5) tissues and in cultured human breast cancer cell lines (6,7). Y1 - 2001 SP - 485 EP - 492 ER - TY - JOUR A1 - Beck, Eberhard A1 - Vincenti, D. A1 - Licht, P. A1 - Berkholz, A. A1 - Jäger, W. A1 - Lang, N. A1 - Merkle, E. T1 - In vitro activity of human chorionic gonadotropin (hCG)--doxorubicin conjugates against ovarian cancer cells JF - In: Anticancer research 20(2000)5A, pg 3001-6 N2 - BACKGROUND Despite radical surgery and the introduction of novel chemotherapeutic agents, the prognosis of ovarian cancer remains poor. Since in the past the potential role of gonadotropins in the induction and progression of ovarian cancer has been discussed, we conjugated doxorubicin to human chorionic gonadotropin (hCG) in order to specifically target ovarian cancer cells. MATERIALS AND METHODS Doxorubicin was conjugated to hCG via glutaraldehyde. 48 hours post seeding, NIH:OVCAR 3 cells were treated with various concentrations of hCG-conjugated and non-conjugated doxorubicin for 2 hours. Cells were cultured for a total of 168 hours. Cell growth was monitored by a crystal violet assay. RESULTS Conjugating doxorubicin to hCG resulted in an average specific uptake of 22 mol doxorubicin per mol protein (range 3.0-43.3 mol). Incubating NIH:OVCAR 3 cells for 2 hours with the conjugate led to a more than 8 fold increase of the IC50 values compared to non-conjugated doxorubicin (0.55 microM versus 4.43 microM). The antiproliferative activity of both conjugated and free doxorubicin was detectable up to 168 hours post treatment. CONCLUSIONS The present experiments clearly demonstrate a more than 8-fold increase in cytotoxicity of the conjugates compared to free doxorubicin. It was also shown that this effect was not restricted to an acute toxic event but that it resulted in a prolonged antiproliferative activity. KW - Antineoplastic Agents KW - Cell Division KW - Cell Survival KW - Chorionic Gonadotropin KW - Drug Synergism Y1 - 2000 SP - 3001 EP - 3006 ER - TY - CHAP A1 - Claus, D. A1 - Beck, Eberhard A1 - Gmeiner, H.J. A1 - Puschmann, E. A1 - Brunhölzl, C. A1 - Jäger, W. A1 - Neundörfer, B. T1 - Neurotoxische Nebenwirkungen von Zytostatika T2 - In: Ophthalmoneurologie, Therapiekontrolle, Prävention : 65. Jahrestagung vom 23. - 26. September 1992 in Saarbrücken/ hrsg. von K. Schimrigk ... Unter Mitwirkung von M. Grundmann ... - Berlin, 1992. - (Verhandlungen der Deutschen Gesellschaft für Neurologie ; 7) (Tagung / Deutsche Gesellschaft für Neurologie ; 65). - ISBN: 3-924171-14-9 Y1 - 1992 SP - 738 EP - 740 ER - TY - CHAP A1 - Beck, Eberhard A1 - Hofmann, M. A1 - Kiesewetter, F. A1 - Jäger, W. A1 - Wildt, L. A1 - Lang, N. T1 - Analysis of CA 125 release by ovarian cancer cells in vitro T2 - In: Tumor associated antigens, oncogenes, receptors, cytokines in tumor diagnosis and therapy at the beginning of the nineties / 6th Symposium on Tumor Markers, Hamburg, [December 9. - 11. 1991] ; Satellite Symposium Cancer of the Breast - State and Trends in Diagnosis and Therapy. Ed. by R. - München [u.a.] : Zuckschwerdt, 1992. - ISBN 3-88603-444-5 Y1 - 1992 SP - 117 EP - 121 ER - TY - CHAP A1 - Beck, Eberhard A1 - Seidinger, M. A1 - Schneider, G. A. A1 - Schuster, M. A1 - Berg, A. A1 - Jäger, W. A1 - Wildt, L. A1 - Lang, N. T1 - Toxische Schädigungen des Gehörs unter Cisplatinhaltiger Chemotherapie bei Patientinnen mit gynäkologischen Tumoren T2 - In: Zytostatikabedingte Nebenwirkungen : Symposium in Pommersfelden, 3. - 4. Juli 1992 ; 26 Tabellen / Bd-Hrsg.: N. Lang ... - München [u.a.] : Zuckschwerdt, 1993. - Aktuelle Onkologie ; 8). - ISBN: 3-88603-458-5 Y1 - 1992 SP - 5 EP - 9 ER - TY - CHAP A1 - Jäger, W. A1 - Löffler, B. A1 - Beck, Eberhard A1 - Bellmann, O. A1 - Wolf, A. A1 - Mund-Hoym, S. A1 - Sauerbrei, W. A1 - Wildt, L. A1 - Lang, N. T1 - Retrospective analysis of GnRH analogue administration in patients with advanced ovarian cancer T2 - In: GnRH analogues and cancer : plus a review of the treatment of uterine leiomyomata; the proceedings of the 2. International Symposium on GnRH Analogues in Cancer and Human Reproduction, Geneva, November 1990 / ed. by B. Lunenfeld. - Carnforth, Lancs. [u.a.] : Parthenon Publ., 1992. - (Advances in the study of GnRH analogues ; 4). - ISBN: 1-85070-328-0 Y1 - 1992 SP - 69 EP - 76 ER - TY - GEN T1 - Lesesaal der Hochschulbibliothek N2 - Lesesaal 1. OG Y1 - 2004 U6 - http://nbn-resolving.de/urn/resolver.pl?urn:nbn:de:kobv:522-opus4-3184 ER - TY - CHAP A1 - Mieke, Christian T1 - Portfoliogestütztes Roadmapping in der Technologievorausschau T2 - In: Interdisziplinarität und Komplexität / Konferenz für Wirtschafts- und Sozialkybernetik KyWi 2012 vom 28. bis 29. Juni 2012 in Aachen. [Gesellschaft für Wirtschafts- und Sozialkybernetik e.V. ; Institut für Unternehmenskybernetik]. Hrsg. von Sabina Jeschke ... - Berlin : Duncker & Humblot , 2012. - (Wirtschaftskybernetik und Systemanalyse ; Bd. 27) 978-3-428-13955-2 Y1 - 2012 SP - 37 EP - 44 ER - TY - CHAP A1 - Mieke, Christian A1 - Braunisch, Dirk T1 - Steuerungsmöglichkeiten für die rückführende Logistik T2 - In: Innovative Produktionswirtschaft : Jubiläumsschrift zu 20 Jahren produktionswirtschaftlicher Forschung an der BTU Cottbus / Christian Mieke ; Dirk Braunisch (Hrsg.) . - Berlin : Logos-Verl., 2012. - (PTI ; Bd. 2) 978-3-8325-3177-5 Y1 - 2012 SP - 292 EP - 312 ER - TY - BOOK ED - Mieke, Christian T1 - Innovative Produktionswirtschaft : Jubiläumsschrift zu 20 Jahren produktionswirtschaftlicher Forschung an der BTU Cottbus KW - Produktionswirtschaft KW - Forschung und Entwicklung KW - Innovationsmanagement KW - Supply Chain Management KW - Wettbewerbsfähigkeit Y1 - 2012 SN - 978-3-8325-3177-5 PB - Logos-Verl. CY - Berlin ER - TY - CHAP A1 - Mieke, Christian T1 - Prozess-Roadmapping - Werkzeug zur Planung von Prozess-Innovationen T2 - In: Innovative Produktionswirtschaft : Jubiläumsschrift zu 20 Jahren produktionswirtschaftlicher Forschung an der BTU Cottbus / Christian Mieke ; Dirk Braunisch (Hrsg.) . - Berlin : Logos-Verl., 2012. - (PTI ; Bd. 2) 978-3-8325-3177-5 Y1 - 2013 SP - 101 EP - 114 ER - TY - JOUR A1 - Löwe, Katharina A1 - Dalijono, Taufan T1 - Entwicklung eines Operatorunterstützungssystems zur Steigerung der Sicherheit hochautomatisierter verfahrenstechnischer Anlagen JF - In: Chemie Ingenieur Technik / Special Issue: 60 Jahre GVT 84 (2012) 11, 2027–2034 Y1 - 2012 SP - 2027 EP - 2034 ER - TY - JOUR A1 - Widiputri, Diah Indriani A1 - Löwe, Katharina A1 - Löher, Heinz-Josef T1 - Systematic approach to incorporate human factors into a process plant design JF - In : Process Safety Progress 28 (2009) 4, S. 347–355 N2 - Despite the increasing number of accidents in process industry caused by human error, there are still too few efforts devoted to this area. This is mainly caused by people's tendency to overestimate human's capability in interacting with their working environment and moreover by the unavailability of reliable analysis methods. Because of the current lack of adequate methods, human factors (HF) analysis is not widely performed in process industry. Some HF techniques developed in the process industry were examined regarding their practical applicability and were unfortunately proved to be unsuitable for an elaborate HF analysis. Therefore, a new approach was developed, which provides a systematic way in performing a qualitative HF analysis to achieve a safer operation and decrease the number of human failure events. HF consideration during the design of a process plant is the key to minimize accidents caused by human error in process industry. Thus, an approach to incorporate HF into design phase is described in this article, which can help achieving a safer operation as early as possible with minimized costs. © 2009 American Institute of Chemical Engineers Process Saf Prog 2009 Y1 - 2009 UR - http://onlinelibrary.wiley.com/doi/10.1002/prs.10328/abstract SN - 1066-8527 SP - 347 EP - 355 ER - TY - JOUR A1 - Löwe, Katharina A1 - Kariuki, S. G. T1 - Integrating Human Factors in the Process Hazard Analysis JF - In: Reliability Engineering & System Safety 92 (2007) 12, pp 1764-1773 Y1 - 2007 SN - 0951-8320 SP - 1764 EP - 1773 ER -